SYGNIS Announces the Global Launch of TruePrime™ Single Cell WGA Kit
SYGNIS Announces the Global Launch of TruePrime™ Single Cell WGA Kit – the first Product of SYGNIS’ TruePrime™ Product Line
• First product launched for single cell DNA amplification
• Product in stock and available for distribution
• SYGNIS launches TruePrime™ online shop for direct ordering
Madrid, Spain and Heidelberg, Germany, January 19th, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the global launch of TruePrime™ Single Cell WGA kit, the first product of its TruePrime™ product line for whole genome amplification (WGA) from single cells.
With the TruePrime™ Single Cell WGA kit, SYGNIS opens up a series of product launches based on its revolutionary novel multiple displacement amplification (MDA) technology for use with various DNA or RNA species for a multitude of applications.
TruePrime™ Single Cell WGA kit launched for DNA amplification from single cells
TruePrime™ Technology – The Revolution in Whole Genome Amplification
Single cell analysis has become one of the most exciting applications in next generation sequencing (NGS) today, as it provides, for example, the accurate analysis of cancer related mutations in cells, taken via biopsies, from different locations in a tumor or characterization of the status of a patient in personalized medicine. The amount of DNA that can be extracted from these samples is limited and needs to be amplified, as frequently DNA is not sufficient for downstream analysis.
Based on the recently discovered primase TthPrimPol, SYGNIS’ TruePrime™ technology stands for a revolutionary way to amplify the amount of DNA or RNA in a sample. While the current gold standard in MDA needs short pieces of DNA (“oligonucleotides”) to start off whole genome amplification, TruePrime™ does not need any synthetic random primers.
The resulting benefits of this innovative approach are enormous and include complete absence of common artifacts linked to the use of oligonucleotides, a reduced amplification bias in genome coverage compared to methods using random synthetic primers, a surpassing reliability as contaminating DNA is not amplified and an exquisite reproducibility when DNA is amplified from single mammalian cells. Moreover, TruePrime™ shows superior sensitivity, is easy to use and works perfectly well with all commonly used NGS platforms such as Illumina and IonTorrent.
The features of the TruePrime™ technology make this product highly attractive for a broad range of next generation sequencing applications and downstream analyses, especially in life science areas such as human genetics, oncology, diagnostics or pathology, where researchers need to obtain biological information from smallest amounts of samples.
“We are very proud and excited about the launch of the first kit of our newly introduced TruePrime™ product line. This launch is a major milestone in our revised corporate product and commercialization strategy to significantly increase control of the Company’s sales channels and revenue streams,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “A first try-out of TruePrime™ Single Cell WGA kit with several key opinion leaders from main European research centers and hospitals showed a very high acceptance rate and proved that SYGNIS is addressing the key challenges in NGS single cell analysis. Based on this encouraging experience and the proven superiority of TruePrime™ over all technologies for whole genome DNA amplification currently available, we are very much looking forward to further releasing TruePrime™ Single Cell WGA kit on to the market and make this launch a success.”
The TruePrime™ Single Cell WGA kit is in stock and will be globally commercialized mainly through distributors as well as through SYGNIS’ newly introduced TruePrime™ online shop under www.sygnis.com/shop. TruePrime™ Single Cell WGA kit is available in two formats, containing 25 or 100 reactions (catalog no.: 350025 or 350100).
SYGNIS has started an intensive promotional mailing campaign to all potential users in the molecular biology field. In addition, the Company plans a wide range of additional marketing events around the product launch including presentations on series of key international scientific meetings and conferences including the US “Advances In Genome Biology and Technologies Meeting” (AGBT) and the “American Association of Cancer Research (AACR) Meeting”, to name just two, publications in renowned scientific journals as well as a special TruePrime™ webinar hosted by the inventor of this technology and scientific board member of SYGNIS, Prof. Luis Blanco in March. The company will make all necessary information for this event available to interested parties on its webpage well in advance.
SYGNIS is currently developing a series of additional TruePrime™ kits for a variety of applications that are expected to be launched during 2015.
TruePrime™ is the brand name of a revolutionary novel multiple displacement amplification technology and one of the key products in SYGNIS’ portfolio. TruePrime™ is based on the combination of the recently discovered polymerase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification.
About the Next Generation Sequencing market
Today, NGS is seen as the fastest-growing and most lucrative segment in the genomics market with an estimated annual growth rate of more than 23% in the years to come. The global NGS market volume today is worth $2.5 billion and is poised to reach $8.7 billion by 2020 (MarketsandMarkets, September 2014). While still mostly used in research institutions, ongoing developments for higher throughput, increased accuracy, and cost efficiency as well as value creating data management will make NGS more and more attractive for commercial applications such as diagnostics, drug discovery, biomarker discovery as well as personalized medicine in clinical laboratories, hospitals and pharma companies.